Latest research on Capecitabine

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Capecitabine dosage

The Cap/Tem regimen schedule includes Capecitabine administration of 600–1,000 mg/m2 bid on days 1–14 and temozolomide 150–200 mg/m2 on days 10–14 on two divided daily doses (Figure 1). [source, 2016]
Because a 20% dose reduction of Capecitabine still evoked adverse effects (general weakness and electrolyte imbalance), chemotherapy with lapatinib alone was started. [source, 2016]
In a Swedish study, patients with KRAS mutations who achieved CR, PR, or SD by receiving chemotherapy in combination with bevacizumab were randomized to receive a metronomic dose of bevacizumab or Capecitabine (500 mg, oral administration, twice daily). [source, 2016]
The combination chemotherapy of Oxaliplatin with 5-FU or Capecitabine for elderly patients has been investigated in phase II trials 39-45 and retrospective studies 46-48, using different doses and schedules. [source, 2016]
Capecitabine was administered at a fixed dose of 2000 mg daily without interruptions. [source, 2016]
Three patients (20%) with Capecitabine experienced both dose adjustment and treatment delay (Table 5). [source, 2016]
Dose adjustment was needed in 20% (38/190) of patients on FOLFOX and in 26.7% (4/15) of those receiving Capecitabine (Table 5). [source, 2016]
Patients received Capecitabine orally at a starting dose of 2,000 mg/m2/day (1,000 mg/m2 twice daily) on days 1 to 14 of a 3-week cycle plus PA-MSHA subcutaneously at a dose of 1 ml every other day (0.5 ml on the first day). [source, 2015]
Capecitabine dose adjustments were performed according to the approved label. [source, 2015]
All eligible patients received at least one dose of Capecitabine and PA-MSHA and were included in the safety analyses. [source, 2015]